Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Iia, Multicenter, Randomized, Third-party Unblinded, Adjuvant-controlled, Multiple Ascending Dose, Safety, Tolerability, And Immunogenicity Trial Of Acc-001 Withqs-21 Adjuvant In Japanese Subjects With Mild To Moderate Alzheimer's Disease.

NCT00959192 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00959192
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00959192 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Iia, Multicenter, Randomized, Third-party Unblinded, Adjuvant-controlled, Multiple Ascending Dose, Safety, Tolerability, And Immunogenicity Trial Of Acc-001 Withqs-21 Adjuvant In Japanese Subjects With Mild To Moderate Alzheimer's Disease.
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2009
Completion date
January 31, 2013
Enrollment
32 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease